A functional search for pharmacogenomic biomarker of the drugs on inflammatory bowel disease, and suggestion of its utilization
Project/Area Number |
24590671
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Applied pharmacology
|
Research Institution | Hyogo University of Health Sciences |
Principal Investigator |
OHNO Masako 兵庫医療大学, 薬学部, 講師 (50467528)
|
Co-Investigator(Renkei-kenkyūsha) |
AZUMA Junichi 兵庫医療大学, 薬学部, 教授 (30144463)
|
Project Period (FY) |
2012-04-01 – 2016-03-31
|
Project Status |
Completed (Fiscal Year 2015)
|
Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2014: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2012: ¥2,860,000 (Direct Cost: ¥2,200,000、Indirect Cost: ¥660,000)
|
Keywords | ファーマコゲノミクス / アザチオプリン / 炎症性腸疾患 |
Outline of Final Research Achievements |
Azathioprine (AZA) is an important immunomodulator used for inflammatory bowel disease. Its use is unfortunately limited due to marked inter-individual differences in responses to the drug. In this study, we found the pharmacogenomic factors that may be involved in safety or efficacy during AZA therapy. The findings suggest that the SNPs contribute to the optimization of low-dose AZA treatment. Educational program was also designed through the study to nurture the clinical research mind of the pharmacy student.
|
Report
(5 results)
Research Products
(2 results)